An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients | Zendy

Claudio Viscoli | Zendy; Raoul Herbrecht | Zendy; Hamdi Akan | Zendy; Liliana Baila | Zendy; A. Sonet | Zendy; Andrea Gallamini | Zendy; Aristoteles Giagounidis | Zendy; Oscar Marchetti | Zendy; Rodrigo Martino | Zendy; Liv Meert | Zendy; Marianne Paesmans | Zendy; Lieveke Ameye | Zendy; Shivaprakash M. Rudramurthy | Zendy; Andrew J. Ullmann | Zendy; Johan Maertens | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients

Author(s) -

Claudio Viscoli,

Raoul Herbrecht,

Hamdi Akan,

Liliana Baila,

A. Sonet,

Andrea Gallamini,

Aristoteles Giagounidis,

Oscar Marchetti,

Rodrigo Martino,

Liv Meert,

Marianne Paesmans,

Lieveke Ameye,

Shivaprakash M. Rudramurthy,

Andrew J. Ullmann,

Johan Maertens

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp355

Subject(s) - neutropenia , caspofungin , medicine , aspergillosis , refractory (planetary science) , adverse effect , clinical endpoint , surgery , phases of clinical research , febrile neutropenia , chemotherapy , gastroenterology , clinical trial , immunology , biology , antifungal , amphotericin b , dermatology , astrobiology

Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research